![]() Celyad Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology. | ![]() Allogene Therapeutics Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer. | ![]() Adaptimmune Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. | |
Founding Date | Founding Date 2007 | Founding Date 2018 | Founding Date 2008 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Mont-Saint-Guibert, BE HQ New York, US | Locations South San Francisco, US HQ | Locations Philadelphia, US HQ Milton, GB Milton, GB Stevenage, GB |
Employees | Employees 17 | Employees 2263% decrease | Employees 4007% decrease |
Valuation ($) | Valuation ($) 11.8 m | Valuation ($) 585.5 m | Valuation ($) 188.5 m |
Financial | |||
Revenue (est.) | Revenue (est.) €21k (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $178m (FY, 2024) |
Cost of goods | Cost of goods €8k (FY, 2025) | Cost of goods N/A | Cost of goods $70k (FY, 2024) |
Gross profit | Gross profit €5.9m (FY, 2025) | Gross profit N/A | Gross profit $178m (FY, 2024) |
Net income | Net income €830k (FY, 2025) | Net income ($190.9m) (FY, 2025) | Net income ($70.8m) (FY, 2024) |
Funding | |||
Total funding raised | Total funding raised N/A | Total funding raised $ 532m | Total funding raised $ 107.5m |

Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer.
View company
Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.
View company